GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in ...

The GSK (LSE:GSK) share price has fallen off its perch. So it may be a good time to research and consider the stock ...

The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock ...

GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer and UCB. The departures coincided with ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

After 24 weeks, GSK saw a statistically significant reduction in monthly itch score in the linerixibat cohort compared to the ...

On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...

GSK plc (NYSE:GSK – Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock traders acquired 26,518 call options on the stock. This represents an increase of ...

Vesalius Therapeutics' deal with GSK centers around discovering and developing new treatments for Parkinson’s disease, and ...

GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...

GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indication of Arexvy (respiratory syncytial virus vaccine, recombinant ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...